NAT2 and urinary bladder cancer: The subjects at age ≤60 years old with NAT2 low acetylator phenotype were at an almost ten-fold increased the risk of developing bladder cancer than carriers of NAT2 high acetylator phenotype (OR=9.96; 95% CI=1.16-85.90) (p=0.037) (Table 4).